;
Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • BL-8040: Phase II amended

    Biokine Therapeutics Ltd., Tel Aviv, Israel BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem, Israel Product: BL-8040 (formerly BKT-140) Business: Cancer Molecular target: CXC chemokine receptor 4 (CXCR4) (NPY3R) …

    Published on 11/24/2014
  • BreathID: Pivotal trial started

    Exalenz Bioscience Ltd. (Tel Aviv:EXEN), Modiin, Israel Product: BreathID Business: Diagnostic Molecular target: NA Description: Breath-based diagnostic that measures liver function Indication: Diagnose clinically …

    Published on 11/24/2014
  • Brilacidin-OM: Phase II start

    Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Brilacidin-OM Business: Other Molecular target: NA Description: Oral rinse formulation of a synthetic defensin mimetic Indication: Treat and prevent oral mucositis …

    Published on 11/24/2014
  • Cometriq cabozantinib: Completed Phase III enrollment

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Product: Cometriq cabozantinib (XL184) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2); c-Met …

    Published on 11/24/2014
  • CSL112: Phase IIb started

    CSL Ltd. (ASX:CSL), Melbourne, Australia Product: CSL112 Business: Cardiovascular Molecular target: Apolipoprotein A-1 (APOA1) Description: Purified apolipoprotein A-1 (APOA1) reconstituted to form HDL for IV infusion …

    Published on 11/24/2014
  • Decuprate: Phase II started

    Wilson Therapeutics AB, Stockholm, Sweden Product: Decuprate (WTX101) (formerly ATN-224) Business: Endocrine/Metabolic Molecular target: Superoxide dismutase 1 (SOD1) Description: Second-generation analog of ammonium …

    Published on 11/24/2014
  • IV ANAVEX 2-73: Phase IIa started

    Anavex Life Sciences Corp. (OTCQB:AVXL), New York, N.ZZZ. Product: IV ANAVEX 2-73 Business: Neurology Molecular target: Sigma-1 receptor; Muscarinic receptor Description: Aminotetrahydrofuran derivative agonist of sigma…

    Published on 11/24/2014
  • NBTXR3: Phase II/III start

    Nanobiotix S.A. (Euronext:NANO), Paris, France PharmaEngine Inc. (GreTai:4162), Taipei, Taiwan Product: NBTXR3 (PEP503) Business: Cancer Molecular target: DNA Description: Crystalline nanoparticles of hafnium oxide …

    Published on 11/24/2014
  • NeuVax nelipepimut-S: Phase II started

    Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore. Dr. Reddys Laboratories Ltd. (NYSE:RDY), Hyderabad, India Product: NeuVax nelipepimut-S (E75) Business: Cancer Molecular target: NA Description: Vaccine consisting of …

    Published on 11/24/2014
  • NovoTTF-100L: Phase I/II started

    Novocure Ltd., Isle of Jersey Product: NovoTTF-100L(O) Business: Cancer Molecular target: NA Description: Non-invasive portable device that disrupts the division of cancer cells in the ovaries using low-intensity, …

    Published on 11/24/2014
  • ONT-10: Phase Ib started

    Oncothyreon Inc. (NASDAQ:ONTY), Seattle, Wash. Product: ONT-10 Business: Cancer Molecular target: Mucin 1 (MUC1) (CD227) Description: Liposomal glycolipopeptide cancer vaccine targeting mucin 1 (MUC1; CD227) Indication:…

    Published on 11/24/2014
  • Oral ANAVEX 2-73: Phase IIa started

    Anavex Life Sciences Corp. (OTCQB:AVXL), New York, N.ZZZ. Product: Oral ANAVEX 2-73 (ANAVEX 2-73) Business: Neurology Molecular target: Sigma-1 receptor; Muscarinic receptor Description: Aminotetrahydrofuran derivative …

    Published on 11/24/2014
  • OTX015: Phase Ib started

    Oncoethix S.A., Lausanne, Switzerland Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Product: OTX015, ZZZ-803 Business: Cancer Molecular target: Bromodomain containing 2 (BRD2); Bromodomain containing 3 (BRD3…

    Published on 11/24/2014
  • OTX015: Phase IIa started

    Oncoethix S.A., Lausanne, Switzerland Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Product: OTX015, ZZZ-803 Business: Cancer Molecular target: Bromodomain containing 2 (BRD2); Bromodomain containing 3 (BRD3…

    Published on 11/24/2014
  • Selinexor: Phase II started

    Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Natick, Mass. Product: Selinexor (KPT-330) Business: Cancer Molecular target: Exportin 1 (XPO1) (CRM1) Description: Oral selective inhibitor of nuclear export (SINE) protein …

    Published on 11/24/2014
  • TNX-201: Phase I started

    Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), New York, N.ZZZ. Product: TNX-201 Business: Neurology Molecular target: NA Description: Single isomer of isometheptene Indication: Treat episodic tension-type headache …

    Published on 11/24/2014
  • Varlilumab: Phase Ib started

    Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass. Product: Varlilumab (CDX-1127) Business: Cancer Molecular target: CD27 Description: Human mAb targeting CD27 Indication: Treat advanced breast or ovarian cancer …

    Published on 11/24/2014
  • ALD403: Phase IIb started

    Alder Biopharmaceuticals Inc. (NASDAQ:ALDR), Bothell, Wash. Product: ALD403, IV ALD403 Business: Neurology Molecular target: Calcitonin gene-related peptide (CGRP) Description: mAb targeting calcitonin gene-related …

    Published on 11/17/2014
  • Bupivacaine: Phase II started

    Moberg Pharma AB (SSE:MOB), Bromma, Sweden Oracain ApS, Lyngby, Denmark Product: Bupivacaine Business: Neurology Molecular target: NA Description: Lozenge formulation of bupivacaine Indication: Treat oral mucositis (OM)…

    Published on 11/17/2014
  • Carbavance: Phase III started

    The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. Product: Carbavance Business: Infectious Molecular target: Beta lactamase (LACTB) Description: Combination of RPX7009, a boron-containing beta lactamase (LACTB) …

    Published on 11/17/2014
  • Carbavance: Phase III started

    The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. Product: Carbavance Business: Infectious Molecular target: Beta lactamase (LACTB) Description: Combination of RPX7009, a boron-containing beta lactamase inhibitor, and …

    Published on 11/17/2014
  • Dutetrabenazine: Phase III started

    Auspex Pharmaceuticals Inc. (NASDAQ:ASPX), La Jolla, Calif. Product: Dutetrabenazine (SD-809) Business: Neurology Molecular target: Vesicular monoamine transporter 2 (VMAT2) (SLC18A2) Description: Deuterium-substituted …

    Published on 11/17/2014
  • DX-2930: Phase Ib expanded

    Dyax Corp. (NASDAQ:DYAX), Burlington, Mass. Product: DX-2930 Business: Inflammation Molecular target: Kallikrein Description: Human mAb against plasma kallikrein Indication: Prevent hereditary angioedema (HAE) attacks …

    Published on 11/17/2014
  • EBOV GP vaccine: Phase I start

    Novavax Inc. (NASDAQ:NVAX), Gaithersburg, Md. Product: EBOV GP vaccine Business: Infectious Molecular target: NA Description: Recombinant glycoprotein nanoparticle vaccine based on the cluster 3 gene sequence in the …

    Published on 11/17/2014
  • Laquinimod: Phase II started

    Active Biotech AB (SSE:ACTI), Lund, Sweden Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Product: Laquinimod (SAIK-MS) Business: Neurology Molecular target: S100 calcium binding protein A9 (S100A9…

    Published on 11/17/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993